Silexion Therapeutics released FY2023 Annual Earnings on March 18, 2025 (EST) with actual revenue of USD 0 and EPS of USD 0

Brief Summary

Silexion Therapeutics reported 2023 fiscal year financial results with no revenue and earnings per share (EPS) of 0 USD.

Impact of The News

The financial results reported by Silexion Therapeutics indicate that the company did not generate any revenue in the 2023 fiscal year, and the EPS was 0 USD. This suggests that the company either did not have any significant commercial activity or product sales during this period, or it is still in the development phase without marketable products. For comparison, other high-tech companies like TSMC and ASML have shown significant revenues and growth in their quarterly earnings. For instance, TSMC reported a revenue of 301 billion USD for the second quarter of 2025, reflecting a 17.8% growth driven by high-performance computing and mobile business recovery . ASML also reported a revenue of 77 billion EUR for the second quarter of 2025, with a 23.2% year-on-year growth . Given the lack of revenue and EPS for Silexion Therapeutics, it stands in stark contrast to its peers and indicates challenges the company might face in achieving financial stability. This could lead to investor concerns and potential stock price volatility. Moving forward, the company’s development trends will depend significantly on its ability to commercialize its products and generate revenue.